Biotheryx
Biotheryx is a biotechnology company focused on developing a pipeline of first-in-class protein degraders for cancer and inflammatory diseases, utilizing its proprietary PRODEGY platform.
Services
Biotheryx offers advanced drug discovery services focused on the development of first-in-class protein degraders. The company's portfolio targets validated areas within cancer and inflammatory diseases, employing a proprietary platform known as PRODEGY for this purpose. The pipeline includes both molecular glues and bifunctional degraders designed to selectively degrade disease-related proteins.
Products
Biotheryx's drug development efforts include BTX-9341, a dual bifunctional degrader of CDK4/6, which has recently received investigational new drug application clearance from the U.S. FDA. This product is part of their broader pipeline, which focuses on targeted protein degraders for oncology and inflammatory diseases. The innovative platform they utilize, PRODEGY, facilitates the creation of these specialized therapeutic agents.
History
Biotheryx has made significant strides in the biotech industry, exemplified by the successful raising of $92 million in Series E financing, aimed at accelerating their commitment to targeted protein degradation technology in oncology. The company has also established a research collaboration and license agreement with Incyte for the discovery of new oncology targets. Additionally, Biotheryx received equity financing from The Leukemia & Lymphoma Society to propel drug development for blood cancer treatments.
Location
Biotheryx is headquartered in San Diego, CA. The strategic location allows for access to a vibrant biotech ecosystem, which aids in their research and development activities. Being in such a hub provides the company with strong opportunities for collaboration and innovation, furthering their mission to advance their protein degrader technology.